NEW YORK, July 13, 2017 /PRNewswire/ --áMizuho Americas today announced the appointment of Difei
Yang as Executive Director, SMID Cap Biotechnology Research, extending the reach of its US healthcare equity analyst team. Based in New York, Yang will report to Head of US Equity Research Sheryl
Yang has been covering the sector for nearly a decade, most recently serving as Managing Director at Aegis Capital. She has also served in senior equity analyst roles at Brean Capital, R.F. Lafferty, WallachBeth Capital and Auriga Global Investors. In addition to her research expertise, Yang has also held senior science and program management roles within the pharmaceutical industry and has authored many granted US patents and peer reviewed scientific publications. She holds a Ph.D. in Chemistry from the University of California Los Angeles as well as an MBA from Georgia State University.
"Continued investment in our US equity research platform to add breadth and depth of investment insight for clients remains a significant area of focus as we grow and expand in this market," said Matt DeSalvo, Head of Equities at Mizuho Americas. "Yang will fortify our robust healthcare sector coverage, bringing to the table abundant research expertise and an esteemed scientific background."
Yang joins a growing Mizuho US healthcare equity research team that includes large cap biotech analyst Salim Syed, as well as analysts covering the healthcare services and pharmaceuticals sectors to deepen coverage and explore small and mid-cap opportunities for biotechnology investors. Mizuho has made a number of equity research appointments in the past year, with the most recent additions being senior internet and fintech analyst hires announced in May.
About Mizuho AmericasMizuho Americas is a leading financial institution comprising several legal entities, which together offer clients corporate and investment banking, financing, securities, treasury services, asset management, research and more. With professionals in offices throughout the US, Canada, Mexico, Brazil and Chile, Mizuho's operations in the Americas connect a broad client base of major corporations, financial institutions and public sector groups to local markets and a vast global network. Learn more at mizuhoamericas.com
Mizuho Americas is an integral part of the Japan-based Mizuho Financial Group, Inc. (NYSE: MFG). Mizuho Financial Group is one of the largest financial institutions in the world, offering comprehensive financial and strategic services including private banking and venture capital through its subsidiaries. The group has over 900 offices and 56,000 employees worldwide in nearly 40 countries throughout the Americas, EMEA, and Asia. At the end of 2016, its total assets were $1.8 trillion. Learn more about Mizuho Financial Group at https://www.mizuho-fg.com
View original content:http://www.prnewswire.com/news-releases/mizuho-expands-healthcare-equity-research-with-smid-cap-biotechnology-hire-300487662.html
SOURCE Mizuho Americas
Subscribe to our Free Newsletters!
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ...
When a person overeats, he is unable to control his hunger pangs, while during an emotional/binge ...
Hypoplastic left heart syndrome is a rare congenital condition, which affects normal blood ...View All